Effective January 1, 2019, VIEKIRA XR and TECHNIVIE will no longer be available in the U.S.A. Until January 1, 2019, supply of these medications will be available for all patients who begin therapy prior to July 1, 2018, to ensure that they are able to obtain product necessary to complete their course of prescribed therapy. Accordingly, AbbVie advises that physicians should cease writing any new prescriptions for VIEKIRA XR and TECHNIVIE effective July 1, 2018.